NorthWest Biotherapeutics Inc (NWBO)

[EMHLondonUK]

Scotty,

It also advances through lab top research into specific mechanisms of action which explain why trials work / don’t work and guide clinician scientists into their next wave of protocol development.

As we’ve seen with the is it Tau is not Tau journey around early and late adult dementia illness families, without a good understanding of the underlying pathways and then the indication’s proposed mechanism of action, we don’t know if the thing actually works.

What was exciting about the mechanism of action was not that the vax just worked as they thought, but that it worked across a broader range of targets than had been previously known, activated a deeper / broader native immune response than expected, and that it could be reenergised again and again to keep the immune response primed and ready to regulate reoccurrence.

Unless I’m missing something, those 3 things are new news and critical to gaining clinical (and regulatory) acceptance moving forward.

Happy to be corrected by people with greater scientific or medical insight than I have, but until I hear from a group of them correcting my understanding, I’m going to be a little more optimistic about these treatments than I was on Friday.